


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**COMPLETION OF REGISTRATION FOR THE CLINICAL RESEARCH OF
DIAMMONIUM GLYCYRRHIZINATE ENTERIC CAPSULES COMBINED WITH
VITAMIN C TABLETS IN THE TREATMENT OF NOVEL CORONAVIRUS
PNEUMONIA**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, in accordance with the information published on the official website of Chinese Clinical Trial Registry, clinical research on the effectiveness and safety of Diammonium Glycyrrhizinate enteric capsules combined with vitamin C tablets in the treatment of novel coronavirus pneumonia has completed the clinical trial registration.

Diammonium Glycyrrhizinate enteric capsules (brand name: Tianqingganping (天晴甘平)) was developed by Chia-Tai Tianqing Pharmaceutical Group Co., Ltd, a subsidiary of the Company. While it was originally suitable for the treatment of acute and chronic hepatitis with elevated alanine transaminase, its efficacy on novel coronavirus pneumonia has currently also attracted attention. The aforesaid clinical research is based on the fact that a large amount of oxygen free radicals will be produced during the reproduction process of novel coronavirus, which will damage the patients’ vital organs. The use of vitamin C to eliminate oxygen free radicals, combined with glycyrrhizinate’s anti-inflammatory effect without inhibiting immunity, will serve as a dual protection for tissues and organs.

The Group has been devoted to the research of glycyrrhizinate compounds. The development of Diammonium Glycyrrhizinate capsules (brand name: Ganlixin (甘利欣)), Diammonium Glycyrrhizinate enteric capsules/Tianqingganping, Magnesium Isoglycyrrhizinate injection (brand name: Tianqingganmei (天晴甘美)), a Category 1 new drug, have successively been completed. Various domestic authorized patents have been obtained and the Group was awarded the National Patent Gold Award and supported by the National Key New Drug Scientific and Technological Project in such research field.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 26 February 2020

As at the date of this announcement, the Board comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.